Please login to the form below

Not currently logged in
Email:
Password:

BMS signs cardiovascular research deal with China's Simcere

Companies widen their existing oncology collaboration in cardiovascular disease

Bristol-Myers Squibb (BMS) has agreed a deal with China's Simcere Pharmaceutical to develop a product to help prevent cardiovascular disease (CVD).

The deal will see the companies work together to develop BMS's investigational compound BMS-795311, with Simcere to run and fund the initial development work.

The compound is a small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP), which works to help raise levels of high-density lipoprotein (HDL). As HDL carries cholesterol, triglycerides and other fats in the blood to the liver, increased levels can help decrease the risk of CVD.

Financial terms were not disclosed but Simcere will receive exclusive rights to develop and commercialise the product in China, while BMS will retain exclusive rights in all other markets.

Dr Francis Cuss, senior vice president, Research, BMS, said the move is part of the company's 'Oyster Strategy' to work with companies in key markets during the early stages in the development of promising investigational medicines in BMS' pipeline.

The deal follows a similar partnership agreed between the two companies last year to co-develop BMS' small-molecule MET/VEGFR-2 inhibitor, BMS-817378, for use in cancer treatment. As per the latest deal, Simcere obtained the drug's rights in China, while BMS retained rights in all other markets.

Cuss commented: “That partnership, focused on an oncology compound, has gone extremely well and we are excited to expand our relationship to include a second collaboration in another therapeutic area. Working together we are building on the strengths of both organisations to develop potential medicines and help patients.”

China is becoming an increasingly important focus for major US and European pharmaceutical companies, due to both its emergence as a crucial healthcare market and because R&D costs tend to be cheaper in the country.

China also recently announced plans to improve drug safety, including the increased monitoring of pharmaceutical companies to address what the State Council described as a 'high-risk stage' in medicinal safety.

Other companies to have made moves into the Chinese market in recent months include Merck & Co with its $1.5bn R&D investment in the country and AstraZeneca's proposed purchase of Chinese generics firm Guangdong BeiKang Pharmaceutical Company.

According to PMGroup's Country Report: China, the healthcare market grew by 26 per cent in the country between 2008 and 2010.

14th December 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Life Brands Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....